Dutalys Gets First Taker for Bispecific Antibody Platform
By Cormac Sheridan
Tuesday, December 18, 2012
Dutalys GmbH, an early stage company developing a bispecific antibody platform, entered a research collaboration with a top 10 pharmaceutical firm that could evolve into a product licensing alliance.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.